Sleep problems are common among ALS patients: Meta-analysis

InSilicoTrials, Axoltis partner to work on potential ALS therapy

InSilicoTrials and Axoltis Pharma are teaming up to advance the development of NX210c, the latter’s lead candidate for treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Axoltis will use InSilicoTrials’ simulation platform to see how well NX210c works in virtual simulations that mimic brain and…

Researcher awarded $10K to advance work on ALS therapy

A professor at Massachusetts General Hospital and Harvard Medical School was awarded $10,000 by Mass General Brigham (MGB) for her work to restore the levels of stathmin-2, a protein that is disrupted in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a related neurodegenerative condition, as a possible…

Reminiscing about our pre-ALS days brings joy

A family friend visited last week, prompting a trip down memory lane to the days long before my husband, Todd, had ALS. My teenage daughter and her boyfriend sat on the couch behind us, while Todd, our friend Abby, and I sat around the kitchen table sharing memories…

New Brunswick adds Albrioza for ALS to its public health plan

New Brunswick is reimbursing, through its public health insurance program, the cost of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) for eligible residents living with amyotrophic lateral sclerosis (ALS). The Canadian province is the country’s fourth to provide public coverage for the oral therapy — marketed in the U.S.

Asthma medicine slows ALS disease progression in small trial

Six months of treatment with clenbuterol, an asthma medication, slowed disease progression in adults with amyotrophic lateral sclerosis (ALS), according to data from a small U.S.-based Phase 2 clinical trial. Despite these promising preliminary findings, more than half the participants withdrew from the study due to side effects. “Nonetheless,…

The best cup of coffee I’ve ever had

Throughout our relationship, my late husband, Jeff, was the partner who most enjoyed taking care of people and things. He built wooden furniture and personal gifts, tended to flowers, and prepared meals from scratch. He got a great deal of satisfaction from going above and beyond for people. Jeff was…

ATH-1105 protects against common ALS, FTD disease mechanisms

Athira Pharma’s experimental therapy ATH-1105 shows anti-inflammatory and neuroprotective effects, promoting neuron growth and reducing damage associated with mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a related condition. The small molecule reduced inflammation and the buildup of a faulty version of TDP-43, a protein that’s…